This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||AKCA / Akcea Therapeutics Inc. (00972L107)|
|President & CEO||Soteropoulos Paula|
|Institutional Shares||22,799,043 - 26.60%|
|Common Shares Outstanding||85,718,372 shares (as of 2018-06-30)|
|Institutional Value||$ 556,674,000 USD|
Institutional Stock Ownership and Shareholders()
Akcea Therapeutics Inc. (NASDAQ:AKCA) has 60 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,799,043 shares.
Largest shareholders include
FMR LLC / Fidelity, Wellington Management Group LLP, Bb Biotech Ag, BlackRock Inc., Vanguard Group Inc, Bellevue Group AG, State Street Corp, Geode Capital Management, Llc, Altrinsic Global Advisors Llc, and Northern Trust Corp.
Akcea Therapeutics Inc. (NASDAQ:AKCA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Delpha Capital Management, Llc||1,521||0||-100.00||26||0||-100.00|
|CITADEL ADVISORS LLC||Call||20,600||36,400||76.70||528||863||63.45|
|CITADEL ADVISORS LLC||Put||9,200||218|
|Sonora Investment Management, LLC||50||50||0.00||1,281||1||-99.92|
|AMERICAN INTERNATIONAL GROUP INC||9,588||8,307||-13.36||246||197||-19.92|
|JP Morgan Chase & Co||4,735||4,318||-8.81||121||102||-15.70|
|BANK OF AMERICA CORP /DE/||6,878||12,368||79.82||176||293||66.48|
|NEW YORK STATE COMMON RETIREMENT FUND||14,800||14,200||-4.05||379||337||-11.08|
|GROUP ONE TRADING, L.P.||Put||3,600||10,500||191.67||92||249||170.65|
|Advisor Group, Inc.||100||2|
|Tower Research Capital LLC (TRC)||1,595||3,477||117.99||41||82||100.00|
|QS Investors, LLC||50||54||8.00||1||1||0.00|
|ProShare Advisors LLC||32,725||37,651||15.05||838||893||6.56|
|TEACHERS ADVISORS INC||27,855||26,257||-5.74||713||623||-12.62|
|MANUFACTURERS LIFE INSURANCE COMPANY, THE||13,015||11,687||-10.20||333||277||-16.82|
|FMR LLC / Fidelity||10,008,016||12,455,383||24.45||256,306||295,317||15.22|
|VIRTUS ETF ADVISERS LLC||39,351||33,315||-15.34||1,008||790||-21.63|
|VANGUARD GROUP INC||1,123,758||1,159,797||3.21||28,779||27,499||-4.45|
|Bellevue Group AG||48,799||379,301||677.27||1,250||8,993||619.44|
|Cutler Group LP||Call||3,000||6|
|ROYAL BANK OF CANADA||59||64||8.47||1||2||100.00|
|Paloma Partners Management Co||9,100||216|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Call||20,700||32,200||55.56||530||763||43.96|
|Virtu Financial LLC||12,571||8,722||-30.62||322||207||-35.71|
|BB BIOTECH AG||2,389,571||2,484,071||3.95||61,197||58,897||-3.76|
|Daiwa Securities Group Inc.||368||368||0.00||9||9||0.00|
|ACADIAN ASSET MANAGEMENT LLC||149||0||-100.00||4||0||-100.00|
|Wellington Management Group LLP||3,384,101||2,604,557||-23.04||86,667||61,754||-28.75|
|Swiss National Bank||28,300||28,300||0.00||725||671||-7.45|
|BNP PARIBAS ARBITRAGE, SA||3,433||685||-80.05||87,919||16,241||-81.53|
|GEODE CAPITAL MANAGEMENT, LLC||207,139||203,131||-1.93||5,304||4,816||-9.20|
|SEI INVESTMENTS CO||8||8||0.00||0||0|
|UBS Group AG||200||219||9.50||5||5||0.00|
|BANK OF MONTREAL /CAN/||90||2|
|Cutler Group LP||127||400||214.96||3||9||200.00|
|FIFTH THIRD BANCORP||150||4|
|CITADEL ADVISORS LLC||8,983||213|
|RidgeWorth Capital Management LLC||18,071||314|
|SCHWAB CHARLES INVESTMENT MANAGEMENT INC||76,142||71,060||-6.67||1,950||1,685||-13.59|
|NORTHERN TRUST CORP||170,924||181,110||5.96||4,378||4,294||-1.92|
|WELLS FARGO & COMPANY/MN||23,865||34,052||42.69||611||807||32.08|
|Metlife Investment Advisors, Llc||7,356||0||-100.00||188||0||-100.00|
|GOLDMAN SACHS GROUP INC||43,777||64,103||46.43||1,121||1,520||35.59|
|ALPS ADVISORS INC||123,368||2,925|
|CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM||23,179||19,516||-15.80||594||463||-22.05|
|CREDIT SUISSE AG/||26,365||14,223||-46.05||676||337||-50.15|
|PIEDMONT INVESTMENT ADVISORS LLC||221||5|
|Zurcher Kantonalbank (Zurich Cantonalbank)||4,300||4,300||0.00||110||102||-7.27|
|Legal & General Group Plc||2,705||1,899||-29.80||69||45||-34.78|
|Iguana Healthcare Management, LLC||100,000||0||-100.00||1,736||0||-100.00|
|METROPOLITAN LIFE INSURANCE CO/NY||5,008||0||-100.00||128,255||0||-100.00|
|STATE STREET CORP||260,309||260,009||-0.12||6,664||6,167||-7.46|
|GROUP ONE TRADING, L.P.||Call||17,900||11,800||-34.08||458||280||-38.86|
|Quantbot Technologies LP||4,089||5,751||40.65||104||136||30.77|
|GREAT WEST LIFE ASSURANCE CO /CAN/||2,062||2,062||0.00||53||49||-7.55|
|DEUTSCHE BANK AG\||16,289||33,829||107.68||416||801||92.55|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Put||25,300||28,000||10.67||648||664||2.47|
|BOOTHBAY FUND MANAGEMENT, LLC||11,400||270|
|Cutler Group LP||Put||800||3,000||275.00||1||7||600.00|
|Ameritas Investment Partners, Inc.||1,275||1,275||0.00||33||30||-9.09|
|Bank of New York Mellon Corp||64,984||56,558||-12.97||1,665||1,341||-19.46|
|ALTRINSIC GLOBAL ADVISORS LLC||187,800||197,800||5.32||4,810||4,690||-2.49|
|TIAA CREF INVESTMENT MANAGEMENT LLC||48,808||32,653||-33.10||1,250||774||-38.08|
|Parallax Volatility Advisers, L.P.||326||0||-100.00||8||0||-100.00|
|JANE STREET GROUP, LLC||20,456||0||-100.00||524||0||-100.00|
|EVENTIDE ASSET MANAGEMENT, LLC||175,000||0||-100.00||4,482||0||-100.00|
|MILLENNIUM MANAGEMENT LLC||12,104||63,998||428.73||310||1,517||389.35|
|PERCEPTIVE ADVISORS LLC||97,144||0||-100.00||2,488||0||-100.00|
|Cubist Systematic Strategies, LLC||7,843||0||-100.00||201||0||-100.00|
2018-08-18 - Asif
Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
Related News Stories
There will be significant competition for the limited number of ATTR patients - approximately 10k with ATTR-PN, 40k with ATTR-CM, and 200k with ATTRwt. (12-0)
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic to ever be approved.
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment—the first therapy indicated for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. (0-2)
Good afternoon, and welcome to the Akcea Therapeutics Second Quarter 2018 Conference Call. As a reminder, this call is being recorded. Leading the call today is Paula Soteropoulos, Akcea’s Chief Executive Officer. Ms. Soteropoulos, please begin.
Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES (42-2)
as of ET